<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01529957</url>
  </required_header>
  <id_info>
    <org_study_id>TG-873870-C-2</org_study_id>
    <nct_id>NCT01529957</nct_id>
  </id_info>
  <brief_title>A Study of Nemonoxacin Malate Sodium Chloride Injection Administered by Intravenous Infusion</brief_title>
  <official_title>A Phase I Clinical Study of Nemonoxacin Malate Sodium Chloride Injection Administered by Intravenous Infusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TaiGen Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TaiGen Biotechnology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of nemonoxacin in
      healthy Chinese volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single dose safety and tolerability study: evaluate safety and tolerability of intravenous
      infusion nemonoxacin 25mg, 50mg, 125mg, 250mg, 500mg, 750mg, 1000mg and 1250mg.

      Single dose pharmacokinetic (PK) study:evaluate PK profile of doses of 250mg, 500mg or 750mg
      intravenous infusion nemonoxacin .

      Multiple dose study: evaluate PK profile of doses of 500mg, 650mg or 750mg intravenous
      infusion nemonoxacin after consecutive 10 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse event assessment in healthy Chinese volunteer</measure>
    <time_frame>46days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated single dose of nemonoxacin in healthy Chinese volunteers</measure>
    <time_frame>32days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of nemonoxacin in healthy Chinese volunteers</measure>
    <time_frame>4days</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">176</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Nemonoxacin Malate Sodium Chloride 25 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nemonoxacin Malate Sodium Chloride 25 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nemonoxacin Malate Sodium Chloride 50 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nemonoxacin Malate Sodium Chloride 50 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nemonoxacin Malate Sodium Chloride 125 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nemonoxacin Malate Sodium Chloride 125 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nemonoxacin Malate Sodium Chloride 250 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nemonoxacin Malate Sodium Chloride 250 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nemonoxacin Malate Sodium Chloride 500 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nemonoxacin Malate Sodium Chloride 500 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nemonoxacin Malate Sodium Chloride 650 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nemonoxacin Malate Sodium Chloride 650 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nemonoxacin Malate Sodium Chloride 750 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nemonoxacin Malate Sodium Chloride 750 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nemonoxacin Malate Sodium Chloride 1000 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nemonoxacin Malate Sodium Chloride 1000 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nemonoxacin Malate Sodium Chloride 1250 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nemonoxacin Malate Sodium Chloride 1250 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nemonoxacin Malate Sodium Chloride</intervention_name>
    <description>Nemonoxacin Malate Sodium Chloride,intravenous injection,once daily</description>
    <arm_group_label>Nemonoxacin Malate Sodium Chloride 25 mg</arm_group_label>
    <arm_group_label>Nemonoxacin Malate Sodium Chloride 50 mg</arm_group_label>
    <arm_group_label>Nemonoxacin Malate Sodium Chloride 125 mg</arm_group_label>
    <arm_group_label>placebol</arm_group_label>
    <arm_group_label>Nemonoxacin Malate Sodium Chloride 250 mg</arm_group_label>
    <arm_group_label>Nemonoxacin Malate Sodium Chloride 500 mg</arm_group_label>
    <arm_group_label>Nemonoxacin Malate Sodium Chloride 650 mg</arm_group_label>
    <arm_group_label>Nemonoxacin Malate Sodium Chloride 750 mg</arm_group_label>
    <arm_group_label>Nemonoxacin Malate Sodium Chloride 1000 mg</arm_group_label>
    <arm_group_label>Nemonoxacin Malate Sodium Chloride 1250 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male or female, aged 18 ~45

          2. A male volunteer should be willing to use a double-barrier contraception until the
             study is completed, and should not make his partner pregnant during the study and
             within 3 months after completing the study

          3. Volunteers who have never used any tobacco or nicotine-containing product within three
             months before use of the investigational product

          4. Volunteers who are willing to abstain from caffeine- or xanthine- containing drinks or
             food within 24h before being enrolled in the study and throughout the study,such as
             coffee and tea,chocolate,alcohol, grapefruit juice,orange juice,etc.

          5. The body mass index (BMI) of the volunteer must be 19~24, and the weight of a male
             should be at least 50kg,and that of a female should be at least 45kg.

          6. Volunteers who are able to sign the informed consent form (ICF) of their own accord.

        Exclusion Criteria:

          1. History of diabetes,or cardiovascular,hepatic or renal disease.

          2. Had surgery or trauma within 6 months prior to this study

          3. Alcohol or drug abuse

          4. HIV, HBV or HCV positive

          5. subject used any known hepatic enzyme inducer/hepatic enzyme inhibitor product within
             30 days prior to the study

          6. Used any prescribed drug (including traditional chinese medicine) within 14 days prior
             to the study

          7. Donated 400ml of blood or plasma within 3 months prior to this study

          8. Have an abnormal laboratory examination value that exceeds the normal range by 10%

          9. Drug allergies

         10. Have cardiac disorders or have a family history of cardiac disorders

         11. Have abnormal 12-lead ECG during screening

         12. Pregnant or lactating

         13. Participated in any study within 3 months prior to this study

         14. according to the investigator's judgment, affect the safety or efficacy evaluation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yingyuan Zhang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital, Fundan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhen Hospital, Capital Medical University Beijing</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kunming General Hospital of Chengdu Military Region</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital, Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Third Military Medical University First Affiliated Hospital</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Third Military Medical University, Third Affiliated Hospital</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gansu Provincial People's Hospital</name>
      <address>
        <city>Gansu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangzhou Red Cross Hospital</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Sun Yat-sen</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hangzhou First People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Third Xiangya Hospital, Central South University</name>
      <address>
        <city>Hunan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital, Central South University</name>
      <address>
        <city>Hunan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangxi Provincial People's Hospital</name>
      <address>
        <city>Jiangxi</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Jiangxi</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>Liaoning</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huai'an First Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Peking</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Peking</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Qingdao University Medical College</name>
      <address>
        <city>Qingdao</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Antibiotics, Huashan Hospital, Fundan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Pudong New Area, Oriental Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>People's Liberation Army General Hospital of Shenyang Military Region</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital,Zhejiang University School of Medicine</name>
      <address>
        <city>Zhejiang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2012</study_first_submitted>
  <study_first_submitted_qc>February 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2012</study_first_posted>
  <last_update_submitted>February 16, 2012</last_update_submitted>
  <last_update_submitted_qc>February 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

